gw9662 and Glomerulonephritis--IGA

Our recent study suggested that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist attenuates inflammatory response in activated tubular epithelial cells in IgA nephropathy (IgAN). Here, we explore thiazolidinediones as new therapeutic additives to established treatment regime of renin angiotensin blockade in IgAN. Human proximal tubular epithelial cells (PTEC) were pretreated with PPAR-gamma agonist, rosiglitazone, and/or angiotensin II (AngII) type 1 receptor (ATR1) blocker (ARB), losartan, followed by activation with the conditioned medium collected from human mesangial cells incubated with pIgA1 (IgA-HMC) from patients with IgAN. IgA-HMC conditioned medium up-regulated expression of ICAM-1, IL-6 and ATR1 and activated NF-kappaB and ERK1/2 in PTEC. Dual treatment of rosiglitazone and losartan provided synergistic effect in reducing ICAM-1, IL-6 and ATR1 expression and NF-kappaB and ERK1/2 activation induced by the conditioned media when compared with monotherapy. Our data suggest that rosiglitazone trans-represses AngII signaling and may offer additional potential when combined with ARB in treating IgAN.

Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Blotting, Western; Cells, Cultured; Culture Media, Conditioned; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Intercellular Adhesion Molecule-1; Interleukin-6; Kidney Tubules; Losartan; Male; Mesangial Cells; NF-kappa B; PPAR gamma; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones